AS 602801Jun Kinase Inhibitor CAS# 848344-36-5 |
- JNK-IN-7
Catalog No.:BCC1672
CAS No.:1408064-71-0
- JNK-IN-8
Catalog No.:BCC1673
CAS No.:1410880-22-6
- CC-401 hydrochloride
Catalog No.:BCC1458
CAS No.:1438391-30-0
- CC-930
Catalog No.:BCC1459
CAS No.:899805-25-5
- DB07268
Catalog No.:BCC1519
CAS No.:929007-72-7
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 848344-36-5 | SDF | Download SDF |
| PubChem ID | 10195250 | Appearance | Powder |
| Formula | C25H23N5O2S | M.Wt | 457.55 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Bentamapimod | ||
| Solubility | DMSO : 14.29 mg/mL (31.23 mM; Need ultrasonic) | ||
| Chemical Name | 2-(1,3-benzothiazol-2-yl)-2-[2-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]pyrimidin-4-yl]acetonitrile | ||
| SMILES | C1COCCN1CC2=CC=C(C=C2)COC3=NC=CC(=N3)C(C#N)C4=NC5=CC=CC=C5S4 | ||
| Standard InChIKey | XCPPIJCBCWUBNT-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C25H23N5O2S/c26-15-20(24-28-22-3-1-2-4-23(22)33-24)21-9-10-27-25(29-21)32-17-19-7-5-18(6-8-19)16-30-11-13-31-14-12-30/h1-10,20H,11-14,16-17H2 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | AS 602801 is an ATP-competitive JNK inhibitor with IC50 of 80 nM, 90 nM, and 230 nM for JNK1, JNK2, and JNK3, respectively.In Vitro:AS 602801 (AS602801) treatment induces cell death and accordingly decreased the number of viable cells in all three cell lines in a dose-dependent manner, suggesting that AS 602801 may have selective cytotoxic activity against neoplastic cells. AS 602801 exhibits cytotoxicity against both serum-cultured non-stem cancer cells and cancer stem cells derived from human pancreatic cancer, non-small cell lung cancer, ovarian cancer and glioblastoma at concentrations that did not decrease the viability of normal human fibroblasts. AS 602801 also inhibits the self-renewal and tumor-initiating capacity of cancer stem cells surviving AS 602801 treatment[2].In Vivo:Treatment of nude mice bearing xenografts biopsied from women with endometriosis (BWE) with 30 mg/kg AS 602801 (AS602801) causes 29% regression of lesion. Medroxyprogesterone acetate (MPA) or progesterone (PR) alone did not cause regression of BWE lesions, but combining 10 mg/kg AS 602801 with MPA caused 38% lesion regression. In human endometrial organ cultures (from healthy women), treatment with AS 602801 or MPA reduced matrix metalloproteinase-3 (MMP-3) release into culture medium. In organ cultures established with BWE, PR or MPA failed to inhibit MMP-3 secretion, whereas AS 602801 alone or MPA + AS 602801 suppresses MMP-3 production. In an autologous rat endometriosis model, AS 602801 causes 48% regression of lesions compared to GnRH antagonist Antide (84%). AS 602801 reduces inflammatory cytokines in endometriotic lesions, while levels of cytokines in ipsilateral horns are unaffected. Furthermore, AS 602801 enhances natural killer cell activity, without apparent negative effects on uterus[3]. References: | |||||
Cell Assay
[2]
PANC-1, A2780, and A549 human cancer cells and IMR90 human normal fibroblasts are treated without (control) or with the indicated concentrations of AS 602801 (2.5, 5, and 7.5 μM) for 3 days. The number of viable cells (left panels) and the percentage of dead cells (right panels) are determined using trypan blue as a vital dye[2].
Animal Administration
[3]
Mice[3]
The 5-week-old athymic (ncr/nude) ovariectomized mice are anesthetized with isoflurane and subcutaneously implanted with a silastic capsule containing 8 μg estradiol. Twenty-four hours later, mice received subcutaneous or intraperitoneal injection with a phosphate-buffered saline (PBS) suspension of 8 to 10 human endometrial tissue fragments/mouse (biopsies obtained from volunteers or patients) on the ventral midline just below the umbilicus. For 24 hours immediately preceding injection, tissue fragments are established as organ cultures treated with 1 nM estradiol, PR, or MPA. Oral administration of AS 602801 is initiated 10 to 12 days following the injection of tissue. Progesterone is provided via a slow-release silastic capsule containing 25 μg PR, and MPA is given by twice-weekly injections (200 mg/kg) along the right flank using a tuberculin syringe. AS 602801 is administered by gavage at a dose of 10 mg/kg and 30 mg/kg/animal for 30 days. Following the completion of treatment, mice are again anesthetized and sacrificed by cervical dislocation for direct examination of lesion size and number. Uteri are measured and weighed, and excised lesions rapidly frozen for further analysis[3].
References:
[1]. Messoussi A, et al. Recent progress in the design, study, and development of c-Jun N-terminal kinase inhibitors as anticanceragents. Chem Biol. 2014 Nov 20;21(11):1433-43.
[2]. Okada M, et al. The novel JNK inhibitor AS602801 inhibits cancer stem cells in vitro and in vivo. Oncotarget. 2016 May 10;7(19):27021-32.
[3]. Palmer SS, et al. Bentamapimod (JNK Inhibitor AS602801) Induces Regression of Endometriotic Lesions in Animal Models. Reprod Sci. 2016 Jan;23(1):11-23.
AS 602801 Dilution Calculator
AS 602801 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.1856 mL | 10.9278 mL | 21.8555 mL | 43.7111 mL | 54.6388 mL |
| 5 mM | 0.4371 mL | 2.1856 mL | 4.3711 mL | 8.7422 mL | 10.9278 mL |
| 10 mM | 0.2186 mL | 1.0928 mL | 2.1856 mL | 4.3711 mL | 5.4639 mL |
| 50 mM | 0.0437 mL | 0.2186 mL | 0.4371 mL | 0.8742 mL | 1.0928 mL |
| 100 mM | 0.0219 mL | 0.1093 mL | 0.2186 mL | 0.4371 mL | 0.5464 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Kinases represent one of the most popular and promising target class in drug discovery. Success in finding new therapeutics will depend on the validation of the kinase chosen with respect to the disease of interest, and on the ability of chemists to design and synthesize inhibitors. AS602801 is a potent and selective JNK inhibitor with therapeutic potential inMS and fibrosis.
In vitro: AS602801 blocked T-lymphocyte proliferation and induced apoptosis. In RRMS CD4t and CD8t cells, AS602801 induced apoptosis genes and expression of surface markers, while in RRMS CD11bt cells it induced expression of innate immunity receptors and co-stimulatory molecules [1].
In vivo: AS602801, the best JNK inhibitors identified so far, were currently evaluated in preclinical studies, based on preliminary promising results in animal model of auto-immune diseases and neuronal apoptosis [1].
Clinical trial: Recently, a phase IIa proof of concept study of the pan-JNK inhibitor bentamapimod (PGL5001, AS602801) for the treatment of inflammatory endometriosis had been terminated.
Reference:
[1] Ferrandi C, Richard F, Tavano P, Hauben E, Barbié V, Gotteland JP, Greco B, Fortunato M, Mariani MF, Furlan R, Comi G, Martino G, Zaratin PF. Characterization of immune cell subsets during the active phase of multiple sclerosis reveals disease and c-Jun N-terminal kinase pathway biomarkers. Mult Scler. 2011;17(1):43-56.
- SSR128129E
Catalog No.:BCC4498
CAS No.:848318-25-2
- EX-527 R-enantiomer
Catalog No.:BCC5595
CAS No.:848193-69-1
- EX-527 S-enantiomer
Catalog No.:BCC5594
CAS No.:848193-68-0
- Alvelestat
Catalog No.:BCC4058
CAS No.:848141-11-7
- HKI 357
Catalog No.:BCC6046
CAS No.:848133-17-5
- 3,4-Dimethoxyphenyl beta-D-glucoside
Catalog No.:BCN4393
CAS No.:84812-00-0
- threo-1-(4-Hydroxy-3-methoxyphenyl)propane-1,2-diol
Catalog No.:BCN1331
CAS No.:848031-94-7
- 5-Epilithospermoside
Catalog No.:BCN4392
CAS No.:84799-31-5
- Lck Inhibitor
Catalog No.:BCC1689
CAS No.:847950-09-8
- RO4929097
Catalog No.:BCC2089
CAS No.:847925-91-1
- Lenalidomide hemihydrate
Catalog No.:BCC4198
CAS No.:847871-99-2
- S 32212 hydrochloride
Catalog No.:BCC6208
CAS No.:847871-78-7
- NCH 51
Catalog No.:BCC2422
CAS No.:848354-66-5
- Vasicinolone
Catalog No.:BCN4394
CAS No.:84847-50-7
- A 582941
Catalog No.:BCC7920
CAS No.:848591-90-2
- P11
Catalog No.:BCC6275
CAS No.:848644-86-0
- Stigmasta-4,25-dien-3-one
Catalog No.:BCN4395
CAS No.:848669-08-9
- Stigmasta-4,22,25-trien-3-one
Catalog No.:BCN4396
CAS No.:848669-09-0
- BIIB021
Catalog No.:BCC2124
CAS No.:848695-25-0
- Gnetin D
Catalog No.:BCN3380
CAS No.:84870-53-1
- p-Hydroxyphenethyl trans-ferulate
Catalog No.:BCN3995
CAS No.:84873-15-4
- Pulsatilla camphor
Catalog No.:BCN8184
CAS No.:90921-11-2
- Betulinic acid 3β-O-alpha-L-rhamnopyranosyl-(1->2)-[β-D-glucopyranosyl-(1->4)]-alpha-L-arabinopyranoside
Catalog No.:BCC8303
CAS No.:848784-87-2
- AZD8931 (Sapitinib)
Catalog No.:BCC3734
CAS No.:848942-61-0
